ESG Data

▶Environment　▶Human Capital　▶Governance

Environment

  Data: Calculated as of the end of each fiscal year

※Totals may differ due to rounding.

◆　Energy input

item Scope unit FY2021 FY2022 FY2023 FY2024 FY2025
Energy input ROHTO Pharmaceutical GJ 326,137 360,005 386,246 364,991 372,366
Consolidated 777,252
Energy intensity (per net sales) ROHTO Pharmaceutical GJ/JPY mn 3.22 3.12 3.00 2.67 2.64
Consolidated 2.26
Renewable energy share ROHTO Pharmaceutical % 0.4 5.7 11.8 17.5 19.4
Consolidated 11.5
item Scope unit FY2021 FY2022 FY2023 FY2024 FY2025
Electricity consumption ROHTO Pharmaceutical MWh 26,055 28,645 30,878 32,222 32,904
Consolidated 120,136
Renewable electricity share ROHTO Pharmaceutical % 1.3 19.8 40.9 55.1 60.9
Consolidated 20.6
City gas and Natural gas ROHTO Pharmaceutical MWh 38,433 39,187 40,740 39,649 40,104
Consolidated 72,565
Petroleum-based fuels ROHTO Pharmaceutical MWh 700 855 797 708 660
Consolidated 28,796
Purchased heat ROHTO Pharmaceutical MWh 389 475 475 389 430
Consolidated 966

※Renewable electricity is the total electricity generated onsite or purchased from renewable sources.

※Fuel consumption is converted to heat energy and reported in MWh.

※Petroleum-based fuels include LPG, gasoline, diesel, heavy fuel oil and kerosene.

◆　Reducing Greenhouse gas (GHG) emissions

GHG emissions

​

Scope FY2021 FY2022 FY2023 FY2024 FY2025
Scope 1 ROHTO Pharmaceutical 7,342 7,388 7,613 6,900 6,697
Consolidated 21,915
Scope 2
　(market-based)		 ROHTO Pharmaceutical 6,906 5,936 5,109 3,322 2,634
Consolidated 44,498
Scope 1 and Scope 2 total ROHTO Pharmaceutical 14,249 13,324 12,722 10,222 9,331
Consolidated 66,413
Scope 3  Category 1
Purchased goods and services		 ROHTO Pharmaceutical 125,066 170,659 195,896 196,544 211,915
Consolidated 463,442
Category 2 
Capital goods		 ROHTO Pharmaceutical 27,126 5,873 13,171 13,865 18,160
Consolidated 30,835
Category 3 
Fuel- and energy-related activities
(not included in Scope 1 or Scope 2)		 ROHTO Pharmaceutical 2,977 3,199 3,396 3,443 3,678
Consolidated 11,662
Category 4
Upstream transportation and distribution		 ROHTO Pharmaceutical 5,248 4,858 4,671 5,096 5,289
Consolidated 15,624
Category 5 
Waste generated in operations		 ROHTO Pharmaceutical 189 166 142 210 208
Consolidated 1,815
Category 6 
Business travel		 ROHTO Pharmaceutical 839 1,800 2,107 2,284 2,486
Consolidated 3,829
Category 7 
Employee commuting		 ROHTO Pharmaceutical 1,482 1,242 1,284 1,363 1,463
Consolidated 4,948
Category 8 
Upstream leased assets		 ROHTO Pharmaceutical 560 511 1,062 949 1,398
Consolidated 1,466
Category 9 
Downstream transportation and distribution）		 ROHTO Pharmaceutical 1,103 1,211 1,329 1,424 579
Consolidated 2,027
Category 10 
Processing of sold products		 ROHTO Pharmaceutical N/A N/A N/A N/A N/A
Consolidated N/A
Category 11 
Use of sold products		 ROHTO Pharmaceutical Excl. Excl. Excl. Excl. Excl.
Consolidated Excl.
Category 12 
End-of-life treatment of sold products		 ROHTO Pharmaceutical 4,104 4,069 4,435 4,357 4,546
Consolidated 9,990
Category 13 
Downstream leased assets		 ROHTO Pharmaceutical 26 28 22 28 102
Consolidated 102
Category 14 
Franchises		 ROHTO Pharmaceutical N/A N/A N/A N/A N/A
Consolidated N/A
Category 15 
Investments		 ROHTO Pharmaceutical N/A N/A N/A N/A N/A
Consolidated N/A
Scope 3 total ROHTO Pharmaceutical 168,720 193,616 227,516 229,563 249,824
Consolidated 545,740

 

GHG emissions intensity

Unit：ｔ-CO2/JPY mn

item Scope FY2021 FY2022 FY2023 FY2024 FY2025
Scope 1 and 2 
emissions intensity (per net sales)		 ROHTO Pharmaceutical 0.141 0.116 0.099 0.075 0.066
Consolidated 0.193
Scope 3
emissions intensity (per net sales)		 ROHTO Pharmaceutical 1.667 1.678 1.765 1.681 1.774
Consolidated 1.588

◆　Water resources※

item Scope unit FY2021 FY2022 FY2023 FY2024 FY2025
Water use (withdrawal) ROHTO Pharmaceutical thousand ㎥ 263.2 275.7 276.0 273.2 267.5
Consolidated 897.3
Municipal water ROHTO Pharmaceutical thousand ㎥ 112.6 126.5 132.3 129.0 127.4
Consolidated 652.6
Groundwater ROHTO Pharmaceutical thousand ㎥ 150.5 149.3 143.7 144.2 140.1
Consolidated 244.7
Water use intensity (per net sales) ROHTO Pharmaceutical ㎥/JPY mn 2.6 2.4 2.1 2.0 1.9
Consolidated 2.6
Water discharge ROHTO Pharmaceutical thousand ㎥ － 273.0 266.6 245.0 232.6
Consolidated 589.0
Water consumption ROHTO Pharmaceutical thousand ㎥ － 53.9 58.5 54.0 59.7

※Coverage: production and R&D sites

◆　Waste※

Waste by treatment method

​

item Scope FY2021 FY2022 FY2023 FY2024 FY2025
Recycling / reuse ROHTO Pharmaceutical 1,648 1,512 1,866 1,433 1,647
Consolidated 5,101
Landfilling ROHTO Pharmaceutical 0 0 0 0 0
Consolidated 283
Incineration with energy recovery
​		 ROHTO Pharmaceutical 1,201 920 674 824 889
Consolidated 1,689
Incineration without energy recovery
​		 ROHTO Pharmaceutical 63 23 27 34 59
Consolidated 553
Disposal method unknown ROHTO Pharmaceutical 0 0 0 0 0
Consolidated 115
Total waste generated ROHTO Pharmaceutical 2,911 2,454 2,567 2,291 2,595
Consolidated 7,740

※Coverage: production and R&D sites

◆　Packaging and container material use

​

​

item Scope FY2021 FY2022 FY2023 FY2024 FY2025
Plastic ROHTO Pharmaceutical － － 6,270 5,659 5,693
Corrugated cardboard ROHTO Pharmaceutical － － 1,654 2,255 2,269
Paper ROHTO Pharmaceutical － － 2,332 2,149 2,231
Glass ROHTO Pharmaceutical － － 144 166 143
Metal ROHTO Pharmaceutical － － 40 24 31
Total waste generated ROHTO Pharmaceutical － － 10,439 10,253 10,366

※Includes packing materials. Plastic figures also include plastics used in certain products.

◆　Chemical substance management

Trends in Nitrogen Oxides (NOx) and Sulfur Oxides (SOx) Emissions

​

item Scope FY2021 FY2022 FY2023 FY2024 FY2025
Nitrogen oxides (NOx) ROHTO Pharmaceutical 24.0 21.5 20.9 28.5 16.6
Sulfur oxides (SOx) ROHTO Pharmaceutical 0 0 0 0 0

Human Capital

Reporting period: Each fiscal year is based on the fiscal year of each Group company. Point-in-time metrics are reported as of each Group company's fiscal year-end, while period metrics reflect results for each Group company's fiscal year.

◆ Employee composition and diversity

Number of employees

Unit: persons

item classification Scope FY2021 FY2022 FY2023 FY2024 FY2025
Number of employees (regular employees *1) Consolidated 6,866 7,176 7,259 9,144 9,292
Number
 of employees by region		 Japan Consolidated 2,652 2,784 2,866 2,922 2,946
Asia Consolidated 3,324 3,500 3,483 5,119 5,214
Americas *2 Consolidated 472 471 484 512 551
Europe *2 Consolidated 374 375 376 530 520
Oceania Consolidated 44 46 50 61 61
​
Number of employees by gender		 men Consolidated 2,890 3,042 3,117 3,686 3,749
woman Consolidated 3,976 4,134 4,142 5,458 5,543

*1  Excludes fixed-term employees, part-time employees, and company officers.

*2  The Americas include Central and South America; Europe includes the Middle East and Africa.

 Percentage of employees by age group

unit:%

item Scope FY2021 FY2022 FY2023 FY2024 FY2025
Under 30 years old Consolidated 22.1 22.4 21.7 21.0 20.8
30-49 years old Consolidated 62.6 61.4 61.1 59.5 59.4
50 years old and over Consolidated 15.2 16.3 17.2 19.5 19.8
Women's empowerment

unit:%

item Scope FY2021 FY2022 FY2023 FY2024 FY2025
Share of women in total workforce Consolidated 57.9 57.6 57.1 59.7 59.7
Share of women in management positions Consolidated 35.5 36.0 36.7 39.1 40.8
Rohto Pharmaceutical 26.0 30.0 32.8 30.0 31.0
Share of women in senior management positions*1​
​		 Consolidated 32.4 34.3 31.0 34.1 40.7
Share of women in middle management positions*1​
​		 Consolidated 45.1 45.7 44.3 38.7 39.9
Share of women in junior management positions*1​
​		 Consolidated 35.2 35.6 37.7 39.9 41.1
Share of women in management positions in revenue-generating functions *2 
​		 Consolidated 39.4 40.5 41.0 42.3 44.9
Share of women in STEM-related positions *3​
​		 Consolidated 52.9 52.8 51.7 51.0 49.9

*1 Senior, middle, and junior management positions are classified based on Group-wide criteria for responsibilities and authority.

*2  Functions directly involved in revenue generation, such as the creation and delivery of products and services and business development. Administrative and support functions are excluded.

*3  Positions requiring expertise related to science, technology, engineering, or mathematics (STEM), in which such knowledge and skills are applied in the course of work.

Average length of service

unit: year

item classification Scope FY2021 FY2022 FY2023 FY2024 FY2025
Average length of service men Rohto Pharmaceutical 15.0 15.3 14.9 14.4 13.9
woman Rohto Pharmaceutical 12.8 13.1 13.6 13.7 13.6
total Rohto Pharmaceutical 13.6 14.0 14.1 14.0 13.8
Average age

Unit: years old

item classification Scope FY2021 FY2022 FY2023 FY2024 FY2025
Average age men Rohto Pharmaceutical 41.8 42.6 42.3 41.9 41.5
woman Rohto Pharmaceutical 41.4 41.8 42.3 42.8 42.6
total Rohto Pharmaceutical 41.5 42.0 42.3 42.3 42.1
Employment of persons with disabilities

unit:%

item Scope FY2021 FY2022 FY2023 FY2024 FY2025
Employment rate of persons with disabilities*1 4 major companies in Japan*2 － － － － 2.8
Rohto Pharmaceutical 2.4 2.3 2.5 2.6 3.0

*1 Calculated in accordance with the methodology prescribed under Japan's Act to Facilitate the Employment of Persons with Disabilities.

*2 The four major companies in Japan are ROHTO Pharmaceutical Co., Ltd., Qualitech Pharma Co., Ltd., ROHTO NITTEN Co., Ltd., and Amato Pharmaceutical Products, Ltd. Together, they account for at least 90% of the total number of employees in Japan (as of March 2026).

◆ Recruitment and employee turnover 

New employee hires

Units: persons / %

item classification Scope FY2021 FY2022 FY2023 FY2024 FY2025
Number of new employee hires men Rohto Pharmaceutical 18
45.0%		 17
36.2%		 55
59.1%		 37
49.3%		 29
48.3%
woman Rohto Pharmaceutical 22
55.0%		 30
63.8%		 38
40.9%		 38
50.7%		 31
51.7%
total Rohto Pharmaceutical 40
100.0%		 47
100.0%		 93
100.0%		 75
100.0%		 60
100.0%
Number of new graduate hired men Rohto Pharmaceutical 10
38.5%		 8
29.6%		 18
51.4%		 23
46.9%		 21
45.7%
woman Rohto Pharmaceutical 16
61.5%		 19
70.4%		 17
48.6%		 26
53.1%		 25
54.3%
total Rohto Pharmaceutical 26
100.0%		 27
100.0%		 35
100.0%		 49
100.0%		 46
100.0%
Number of mid-career hires* men Rohto Pharmaceutical 8
57.1%		 9
45.0%		 37
63.8%		 14
53.8%		 8
57.1%
woman Rohto Pharmaceutical 6
42.9%		 11
55.0%		 21
36.2%		 12
46.2%		 6
42.9%
total Rohto Pharmaceutical 14
100.0%		 20
100.0%		 58
100.0%		 26
100.0%		 14
100.0%

*Includes rehires

Employee turnover rates

unit:%

item Scope FY2021 FY2022 FY2023 FY2024 FY2025
Voluntary employee turnover rate *1 Consolidated 13.2 12.6 12.4 12.2 14.9
Rohto Pharmaceutical 2.2 3.1 1.7 1.4 2.1
Total employee turnover rate Consolidated 14.4 13.3 13.1 13.0 16.2
Rohto Pharmaceutical 2.4 3.1 2.0 1.5 2.4

* Voluntary turnover excludes mandatory retirement, death in service, and employer-initiated separations. For ROHTO Pharmaceutical, the definition was revised from FY2025 to align with the consolidated basis.

◆ Compensation

Average annual salary of employees
item Scope unit FY2021 FY2022 FY2023 FY2024 FY2025
Average annual salary Rohto Pharmaceutical thousand yen 7,566 7,819 8,176 8,261 8,505
​
Year-on-year change in average annual salary		 Rohto Pharmaceutical % － － － － 2.9
Ratio of women's pay to men's pay
(all employee) *		 Rohto Pharmaceutical % － 60.6 62.1 65.8 67.8

* The ratio represents women's pay as a percentage of men's pay. 

There are no gender-based differences in pay structures or compensation systems. The difference is mainly attributable to factors such as differences in length of service and representation in higher job grades between men and women.

◆ Workstyle and work -life balance support

Utilization of childcare support programs
item classification Scope unit FY2021 FY2022 FY2023 FY2024 FY2025
Parental leave uptake rate
​		 men 4 major companies in Japan % － － － 88.7 91.4
men Rohto Pharmaceutical % 22.2 26.5 46.4 97.5 92.3
woman Rohto Pharmaceutical % 100.0 97.6 100.0 100.0 100.0
​
Number of employees using reduced working hours for childcare*		 men Rohto Pharmaceutical ​ 0 1 1 6 3
woman Rohto Pharmaceutical ​ 128 103 135 143 144

*Number of regular employees who have continuously worked reduced hours for childcare for at least one month. Temporary arrangements lasting less than one month are excluded.

Overtime work and annual paid leave
item Scope unit FY2021 FY2022 FY2023 FY2024 FY2025
​
Overtime work per employee 		 4 major companies in Japan hours / month － － － － 11.7
Rohto Pharmaceutical hours / month 14.7 14.9 13.3 12.3 11.7
Annual paid leave utilization rate
​		 4 major companies in Japan ％ － － － － 80.6
Rohto Pharmaceutical ％ 68.6 72.9 80.0 76.9 80.5
Percentage of employees taking 5 or more consecutive days of leave
​		 Rohto Pharmaceutical ％ 41.7 35.1 36.9 34.5 37.8

◆ Human capital development, career, and well-being

Human capital development
item Scope unit FY2021 FY2022 FY2023 FY2024 FY2025
Average training hours per employee Rohto Pharmaceutical hours / year 7 34 37 49 27
Average training expenditure per employee Rohto Pharmaceutical thousand yen 81 83 101 110 110
Internal double jobs and  external challenge work

Unit: persons

item Scope FY2021 FY2022 FY2023 FY2024 FY2025
Number of employees participating in Internal Double jobs 
​		 Rohto Pharmaceutical 123 123 192 207 233
Number of employees engaged in External Challenge Work 
​		 Rohto Pharmaceutical 52 49 61 65 76
Well-being survey score (engagement)

Unit: points

item Scope FY2021 FY2022 FY2023 FY2024 FY2025
Average score across five items* Rohto Pharmaceutical － 6.84 6.89 6.98 6.99

* Annual average score based on employees' self-assessment of their well-being, with each item rated on a 10-point scale.

◆ Health and productivity management

Health indicators (health KPIs)
classification item Scope unit FY2021 FY2022 FY2023 FY2024 FY2025
Outcome indicators
(physical health)		 Percentage of employees with or at risk of metabolic syndrome
​
​
​		 Rohto Pharmaceutical ％ 14.1 14.8
（6.1＋8.7）		 14.2
（6.1＋8.1）		 15.4
（5.9＋9.5）		 14.9
（6.5＋8.4）
Percentage of women with anemia*1
 ​		 Rohto Pharmaceutical ％ 14.8 14.2 15.9 14.5 14.5
Percentage of employees whose kenryoku Age is lower than their actual age*2
​		 Rohto Pharmaceutical ％ － 62.6 67.3 67.2 64.0
Behavioral indicators
(lifestyle)		 Percentage of employees who smoke Rohto Pharmaceutical ％ 1.9 2.8 2.2 2.6 2.0
Percentage of employees whose alcohol consumption is within the recommended limit*3
​		 Rohto Pharmaceutical ％ 74.2 76.9 76.5 77.2 76.5
Percentage of emploees satisfied with their Sleep*4
(employees sleeping at least six hours)
​		 Rohto Pharmaceutical ％ － 34.5
（58.6）		 47.9
（58.5）		 47.5
（55.9）		 49.9
（56.6）
Percentage pf employees engaging in at least 30 minutes of exercise at least twice a week
​		 Rohto Pharmaceutical ％ 39.0 38.3 41.4 43.1 44.2
Percentage of employees achieving 8,000 steps and 20 minutes of brisk walking per day
​
​		 Rohto Pharmaceutical ％ 14.9
（52.3※5）		 16.5
（54.9※5）		 15.2
（43.4※5）		 11.7
（46.5※5）		 11.8
（48.8※5）
Fulfillment indicators
(mindset)		 Percentage of employees sending 39 (Thank You) Messages *6
(percentage receiving messages)		 Rohto Pharmaceutical ％ － 67.9
（89.6）		 69.5
（89.2）		 68.9
（90.0）		 68.4
（90.3）
Percentage of employees putting learning into practice Rohto Pharmaceutical ％ － － － 62.4 61.2
Overtime hours per employee
​		 Rohto Pharmaceutical hours / month 14.7 14.9 13.3 12.3 11.7
Percentage of employees taking 5 or more consecutive days of leave
​		 Rohto Pharmaceutical ％ 41.7 35.1 36.9 34.5 37.8

*1 Anemia is defined as a hemoglobin level of less than 12.0 g/dL.

*2 Kenryoku Age < Actual Age is defined as cases where at least two of the three physical fitness assessment results—fitness age, walking age, and Brain Fitness®—are lower than the employee's actual age.

*3 The recommended alcohol consumption limit is defined as less than two go (a Japanese sake-equivalent unit) per occasion for men and less than one go per occasion for women.

*4 Percentage of respondents who selected “very satisfied” or “somewhat satisfied” on a four-point scale. In FY2022, a five-point scale including a neutral response option was used.

*5 Average over the period during which the event was held.

*6 An internal messaging tool that allows employees to express their gratitude to one another.

Health checkups and stress checks

unit:%

item Scope FY2021 FY2022 FY2023 FY2024 FY2025
Health checkup participation rate 4 major companies in Japan － － － － 100
Rohto Pharmaceutical － 100 100 100 100
Stress check
participation rate		 Rohto Pharmaceutical － 94.6 98.8 99.8 99.8

◆ Occupational health and safety

Work-related injuries *1
item Scope unit FY2021 FY2022 FY2023 FY2024 FY2025
Serious work-related injuries and illnesses *2 Consolidated cases 0 0 0 2 0
Lost time injuries: 4 or more lost workdays *3 Consolidated cases 10 18 16 19 15
Lost-time-injuries: 1-3 lost workdays Consolidated cases 4 13 12 25 6
Non-lost-time injuries Consolidated cases 13 26 34 18 43
Lost-time injury frequency rate
（LTIFR）*4		 Consolidated － 0.96 2.11 1.87 2.30 1.08

*1 The reporting scope comprises the companies consolidated in each fiscal year. Newly consolidated companies are included from the fiscal year in which they enter the scope of consolidation, and prior-year data are not retrospectively restated. 

The reporting scope expanded significantly from FY2024 with the addition of Eu Yan Sang International Ltd, MoNo chem-pharm Produkte GmbH, Sigmapharm Arzneimittel GmbH, and other companies.

*2 Serious work-related injuries and illnesses resulting in death or permanent disability.

*3: Lost-of-work injuries and non-lost-of-work injuries refer to work-related injuries, and the distinction between lost-of-work and non-lost-of-work injuries is based on the laws and regulations of each country and region.

*4  The lost-time injury frequency rate (LTIFR) is calculated as the number of work-related injuries resulting in one or more lost workdays divided by total hours worked, multiplied by 1,000,000.

◆ Labor-management relations

Labor-Management Relations
item Scope unit FY2021 FY2022 FY2023 FY2024 FY2025
Number of labor union members Rohto Pharmaceutical ​ 1,476 1,498 1,612 1,690 1,707
Labor union membership rate Rohto Pharmaceutical ％ 92.2 92.3 92.0 95.6 95.6

Governance

  Data: Calculated as of the end of each fiscal year

◆ Corporate Governance

Board of Directors and Board of Auditors Composition

Units: persons, years

FY2021 FY2022 FY2023 FY2024 FY2025 As of August 2026
Board of directors total 9 11 11 13 14 14
Outside Director 3
33.3%		 4
36.4%		 4
36.4%		 5
38.5%		 5
35.7%		 5
35.7%
Female Director 2
22.2%		 3
27.3%		 3
27.3%		 4
30.8%		 6
42.9%		 6
42.9%
Average length of service 7.1 6 6.5 6.2 6.1 7.1
Board of Auditors total 4 4 4 4 5 5
Outside Audit & Supervisory Board Member 2
50.0%		 2
50.0%		 2
50.0%		 2
50.0%		 3
60.0%		 3
60.0%
Female auditor 0
0%		 0
0%		 0
0%		 1
25.0%		 2
40.0%		 2
40.0%

*As of March 31st of each fiscal year. However, the average length of service is as of the end of June. Note that past terms of service as a director are not included if the director was reappointed after stepping down.

Activity Status
FY2022 FY2023 FY2024 FY2025
Board of directors Number of times held 8 8 8 8
Average attendance rate* 99.1% 99.2% 97.8% 100%
Nomination committee Number of times held 3 4 3 3
Average attendance rate 100% 100% 100% 100%
Compensation committee Number of times held 4 4 3 3
Average attendance rate 100% 100% 100% 100%
Board of Auditors Number of times held 28 17 18 18
Attendance rate 100% 100% 98.6% 100%

*Includes directors and auditors

Executive Compensation Status

Units: million yen, people

FY2021 FY2022 FY2023 FY2024 FY2025
Directors
(Excluding outside directors)		 Total amount of compensation, etc. 393 441 445 496 539
Rewards, etc.
Total amount by type		 Fixed Compensation 353 391 395 446 473
Performance-linked Compensation 40 50 50 50 66
Number of officers subject to the requirement 6 7 9 9 10
Auditor
(Excluding Outside Audit & Supervisory Board Member)		 Total amount of compensation, etc. 39 40 41 42 43
Rewards, etc.
Total amount by type		 Fixed Compensation 39 40 41 42 43
Performance-linked Compensation － － － － －
Number of officers subject to the requirement 2 2 2 2 2
Outside Director Total amount of compensation, etc. 40 46 51 61 73
Rewards, etc.
Total amount by type		 Fixed Compensation 40 46 51 61 73
Performance-linked Compensation － － － － －
Number of officers subject to the requirement 5 7 6 7 9

◆ Risk Management

Supplier CSR Assessment
FY2021 FY2022 FY2023 FY2024 FY2025
Number of suppliers － － 44 70 －
Response rate － － 100% 100% －
Percentage of total procurement value
among Tier-1 suppliers		 － － 80% 90% －

*Regular surveys will be conducted every two years starting in fiscal year 2024.

◆ Compliance

Hotline Reports and Consultations

Unit: cases

FY2024 FY2025
Japan Outside Japan Total waste generated Japan Outside Japan Total waste generated
Discrimination / Harassment 5 6 11 12 0 12
Workplace Environment / Communication 12 3 15 20 4 24
Labor Management 5 1 6 2 3 5
Proper Business Conduct 2 0 2 2 0 2
Morality 4 0 4 1 0 1
Suspected Misconduct 4 2 6 2 4 6
Others 0 0 0 2 1 3
Total waste generated 32 12 44 41 12 53
Number of Violations

Unit: cases

FY2024 FY2025
Japan Japan Outside Japan Total waste generated
Corruption or Bribery 0 0 0 0
Leakage of Customer Personal Information 0 0 0 0
Conflict of Interest Transactions 0 0 0 0
Money laundering
or insider trading		 0 0 0 0
Dismissal for Disciplinary Reasons 0 0 1 1
Others 1*1 0 1*2 1

*1 Corrective order for violation of the Act against Unjustifiable Premiums and Misleading Representations (Japan)

*2 Administrative measure due to discrepancy in cosmetics notification details (Vietnam)

Rohto Pharmaceutical official account

  • Rohto Pharmaceutical Official X
  • Rohto Pharmaceutical Official Facebook
  • Rohto Pharmaceutical Official Youtube
  • Rohto Pharmaceutical Official Instagram
  • Rohto Pharmaceutical official note
  • Rohto Pharmaceutical Official LINE